Analyst firms · Morgan Stanley · KYMR

Morgan Stanley KYMR price target and rating history

Kymera Therapeutics Inc. (KYMR) · Health Care

Morgan Stanley rates Kymera Therapeutics Inc. (KYMR) Overweight with a $70 price target, as of its latest action on Jul 3, 2025. It has published 5 rating actions on KYMR since July 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.

Current rating
Overweight
Price target
$70
Median target, all firms
$133
Actions on KYMR
5

Morgan Stanley price target on KYMR

$79$73$6620222023202420252026
Morgan Stanley price target on KYMR, each point a stated target, July 2021 to July 2025.

Every Morgan Stanley rating on KYMR

How other firms rate KYMR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Raymond JamesOutperform$140Oct 9, 2026
Wolfe ResearchOutperform$180Sep 10, 2026
Deutsche BankHold$120Jul 30, 2026
Canaccord GenuityBuy$106May 6, 2026
JefferiesBuyMar 16, 2026
BarclaysOverweight$133Jan 28, 2026

Questions about Morgan Stanley and KYMR

What is Morgan Stanley's price target for KYMR?
Morgan Stanley's latest stated price target for Kymera Therapeutics Inc. (KYMR) is $70, from its action on Jul 3, 2025.
What is Morgan Stanley's rating on KYMR?
Morgan Stanley rates KYMR Overweight, a bullish rating, as of Jul 3, 2025.
When did Morgan Stanley last change its view on KYMR?
On Jul 3, 2025, Morgan Stanley resumes coverage at Overweight, price target $70.
How does Morgan Stanley's KYMR target compare with other analysts?
Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.

More KYMR rating histories

All Morgan Stanley ratingsKYMR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.